In most cases (90-95%), back pain is non-specific and cannot be reliably linked to a specific cause or underlying disease.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The U.S. Department of Agriculture’s Economic Research Service projects that by 2050, the total production of global ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Cannabis is big business in Rhode Island. There has been a significant change in policy in Rhode Island, first with the legalization of medical marijuana in 2006 and then the legalization of personal ...

Cholesterol absorption inhibitors, like statins, are associated with a reduced risk of developing liver cancer. Previous ...

Montana’s small, independent pharmacies say they’re getting increasingly squeezed on reimbursements by pharmacy benefit ...

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous ...

The DRUG Act will put downward pressure on drug prices and insurance premiums by breaking this cycle. It will increase transparency in the drug pricing process, protect local pharmacies from unfair ...

Jonathan Levitt, a lawyer who helps clients sue PBMs, says the best defense is getting and analyzing as much information as ...

Medicare covers lupus treatment in different ways depending on your age and how the condition affects you. Read more.

Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...